Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Allogene Therapeutics (ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune disease, has scheduled its fourth quarter and full year 2024 financial results announcement for March 13, 2025, after market close.
The company will host a conference call and webcast at 2:00 PM PT/5:00 PM ET on the same day. Investors can access the listen-only webcast through Allogene's website, with a replay available for approximately 30 days. Those wishing to participate in the Q&A session must register separately to receive a personal PIN for call access.
Allogene Therapeutics (ALLO), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie CAR T allogeniche (AlloCAR T™) per il cancro e le malattie autoimmuni, ha programmato l'annuncio dei suoi risultati finanziari del quarto trimestre e dell'anno intero 2024 per il 13 marzo 2025, dopo la chiusura del mercato.
L'azienda ospiterà una conferenza telefonica e un webcast alle 2:00 PM PT/5:00 PM ET lo stesso giorno. Gli investitori possono accedere al webcast in modalità ascolto solo tramite il sito web di Allogene, con una registrazione disponibile per circa 30 giorni. Coloro che desiderano partecipare alla sessione di domande e risposte devono registrarsi separatamente per ricevere un PIN personale per l'accesso alla chiamata.
Allogene Therapeutics (ALLO), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias CAR T alogénicas (AlloCAR T™) para el cáncer y enfermedades autoinmunitarias, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 13 de marzo de 2025, después del cierre del mercado.
La empresa llevará a cabo una conferencia telefónica y un webcast a las 2:00 PM PT/5:00 PM ET el mismo día. Los inversores pueden acceder al webcast solo para escuchar a través del sitio web de Allogene, con una repetición disponible durante aproximadamente 30 días. Aquellos que deseen participar en la sesión de preguntas y respuestas deben registrarse por separado para recibir un PIN personal para acceder a la llamada.
Allogene Therapeutics (ALLO)는 암 및 자가면역 질환을 위한 동종 CAR T(AlloCAR T™) 치료법 개발에 집중하는 임상 단계의 생명공학 회사로, 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 13일 시장 종료 후로 예정했습니다.
회사는 같은 날 오후 2시 PT/오후 5시 ET에 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다. 투자자는 Allogene의 웹사이트를 통해 청취 전용 웹캐스트에 접근할 수 있으며, 약 30일 동안 재생이 가능합니다. Q&A 세션에 참여하고자 하는 분은 별도로 등록하여 전화 접근을 위한 개인 PIN을 받아야 합니다.
Allogene Therapeutics (ALLO), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies CAR T allogéniques (AlloCAR T™) pour le cancer et les maladies auto-immunes, a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 13 mars 2025, après la fermeture du marché.
L'entreprise organisera une conférence téléphonique et un webcast à 14h00 PT/17h00 ET le même jour. Les investisseurs peuvent accéder au webcast en mode écoute uniquement via le site Web d'Allogene, avec une rediffusion disponible pendant environ 30 jours. Ceux qui souhaitent participer à la session de questions-réponses doivent s'inscrire séparément pour recevoir un code PIN personnel pour accéder à l'appel.
Allogene Therapeutics (ALLO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allogenen CAR T (AlloCAR T™) Therapien für Krebs und Autoimmunerkrankungen konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 13. März 2025 nach Börsenschluss angesetzt.
Das Unternehmen wird am selben Tag um 14:00 Uhr PT/17:00 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten. Investoren können über die Website von Allogene auf den nur hörbaren Webcast zugreifen, der etwa 30 Tage lang verfügbar sein wird. Interessierte, die an der Q&A-Session teilnehmen möchten, müssen sich separat registrieren, um einen persönlichen PIN für den Zugang zum Anruf zu erhalten.
- None.
- None.
- Conference Call and Webcast Scheduled for March 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the fourth quarter and full year 2024 financial results and provide a business update on March 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
Listen-Only Webcast
The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.
Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X (formerly Twitter) and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” heading in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ
When will Allogene Therapeutics (ALLO) release its Q4 and full year 2024 earnings?
How can investors access ALLO's Q4 2024 earnings call?
What time is Allogene's (ALLO) Q4 2024 earnings call scheduled for?
How long will ALLO's Q4 2024 earnings call replay be available?
